Literature DB >> 10096958

Inherited Thrombophilia due to Factor V Leiden Mutation.

.   

Abstract

Inherited thrombophilia due to activated protein C resistance is now recognized as one of the major genetic risk factors in the development of venous thromboembolic disease. Activated protein C resistance is secondary to a point mutation in the factor V gene, factor V Leiden. The high prevalence of this mutation in the general population, mainly in Caucasians of European descent, is a major contributing factor to the high incidence of venous thromboembolic disease in the United States, affecting one in 1000 individuals annually. Heterozygosity and homozygosity for factor V Leiden increase the risk for thrombosis 5- to 10-fold and 50- to 100-fold, respectively, compared with genotypically normal individuals. Factor V Leiden is more common than all other known genetic risk factors for thrombosis, and its presence results in a compounded risk in patients with simultaneous inherited abnormalities such as protein C, protein S, antithrombin III deficiencies, hyperhomocysteinemia, and/or acquired risk factors. Therefore, detection of activated protein C resistance and genotyping for factor V Leiden are important for establishing risk for thrombosis and ultimately for patient management.

Entities:  

Year:  1998        PMID: 10096958     DOI: 10.154/MODI00300055

Source DB:  PubMed          Journal:  Mol Diagn        ISSN: 1084-8592


  3 in total

1.  Severe thrombotic and bleeding complications in a baby with heterozygous factor V Leiden and acquired von Willebrand disease on ECMO.

Authors:  Ozlem Bilen; Laura Loftis; Jun Teruya
Journal:  J Extra Corpor Technol       Date:  2011-06

2.  Near real-time immuno-optical sensor for diagnosing single point mutation: a model system: sensor for factor V Leiden diagnosis.

Authors:  Kyung A Kang; Yongjie Ren; Vivek R Sharma; Stephen C Peiper
Journal:  Biosens Bioelectron       Date:  2009-02-20       Impact factor: 10.618

3.  Prevalence of thrombophilic mutations in patients with unprovoked thromboembolic disease. A comparative analysis regarding arterial and venous disease.

Authors:  E Mandala; C Lafaras; C Tsioni; M Speletas; A Papageorgiou; D Kleta; T Dardavessis; G Ilonidis
Journal:  Hippokratia       Date:  2012-07       Impact factor: 0.471

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.